Beijing Cycloud invites you to participate in the Companion Diagnostic & Biomarker Precision Medical Summit 2018

The CEO of Stilla Technologies, Remi Dangla was invited to participate in the “Companion Diagnostic & Biomarker Precision Medical Summit 2018” on Apirl 26-27th 2018, and he will make an excellent speech on “the application of the advanced three-channel detection platform Naica^TM system in companion diagnostics”.

Rémi Dangla  CEO of Stilla Technologies

Beijing Cycloud Biotech Co., Ltd. will take products to Shanghai Dongyi Hotel (No. 555, lilac Road, Pudong, Shanghai), on Apirl 26-27th 2018, for participating the Companion Diagnostic & Biomarker Precision Medical Summit 2018. We will wait for your visit at Booth A1.

The theme of this conference: accompanying diagnosis, targeted therapy, biomarkers, liquid biopsy and other technological developments, promoting the development of precision medicine and personalized medicine.

Precision Medicine is based on personalized medicine. Liquid biopsy obtains tumor information through non-invasive sampling and assists in cancer treatment. It is a representative diagnostic technology for "precise medical treatment". Companion Diagnosis (CDx) is the key to achieving precision medicine. PCR, NGS gene sequencing, molecular diagnosis is the basis for accurate diagnosis; and cellular immunotherapy, targeted therapy, biomarkers and accompanying diagnosis are the basis of precision treatment. In order to promote communication between people engaged in precision medical / molecular diagnostics / gene sequencing / oncology treatment / accompanying diagnostics development, Asia Companion Diagnostic and Precision Medicine Summit 2018 invited famous research institutes, government departments, pharmaceutical companies, diagnostic companies from Asia Leading industry leaders, together with diagnostic policies, market and commercialization, biomarkers, sequencing technology, precision medical policy, precise tumor therapy, single-molecule sequencing, etc., to discuss Asian concomitant diagnosis and precision medicine future.

Main topics of the conference：

> Regulatory and Market of Asia CDx

> In vitro diagnosis in Japan

> Regulatory innovation to promote the joint development of diagnosis

> With the direction of diagnostic market in Asia, how do pharmaceutical companies lay out the "drug-diagnostic" model of diagnostic market and jointly develop regulatory strategies to cope with it

> The development of individualized drug use by biomarkers

> Selection and cost considerations of early clinical biomarkers

> How to accelerate drug innovation, reduce cycle and development risks with diagnosis

> Under the same new drug development process: how can pharmaceutical companies and diagnostics win

> Clinical detection of tumor diagnosis and immunotherapy

> Clinical application and tracking of tumor molecular diagnosis in precise treatment of tumor with diagnostic strategy

> Circulating tumor cells, circulating tumor DNA, exocrine and circulating RNA